ArticleMolecular diversity2026
LKE-DTA: predicting drug-target binding affinity with large language model representations and knowledge graph embeddings.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DCI-SiteDTA: drug-target affinity prediction based on binding sites detection and site-aware dual cross-interaction block.BMC bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Accurate prediction of drug-target binding affinity (DTA) is pivotal for drug discovery, yet current computational methods struggle to integrate heterogeneous biomedical knowledge and capture complex molecular interactions. We present LKE-DTA, a novel deep learning framework that synergistically integrates large language models (LLMs) with knowledge graphs (KGs) to create comprehensive multi-dimensional representations for drugs and proteins. Besides, we propose a Dual Multi-Head Attention mechanism that dynamically fuses heterogeneous embeddings and captures complex dependencies, thereby significantly enhancing predictive accuracy. On benchmark datasets, comprehensive evaluations under fivefold cross-validation demonstrate that LKE-DTA consistently outperforms state-of-the-art methods. On Davis, it reduces MSE and MAE by 14.7% and 8.2%, increases CI and r by 0.9% and 3.4%. On KIBA, it achieves reductions of 4.6% in MSE and 5.3% in MAE, with improvements of 0.8% in CI and 1.5% in r, while maintaining robust convergence. In cold-start evaluation, LKE-DTA shows strong generalization: in the Cold Drug setting, CI and r improve by 2.4% and 9.6%; in the Cold Target setting, MSE, MAE, CI, and r improve by 10.2%, 12.2%, 6.6%, and 9.0%. On an independent test set, it achieves the lowest MSE and MAE and the highest CI and r, surpassing the best baseline by 9.5%, 13.0%, 6.6% and 9.6%, respectively. This work demonstrates the significant potential of combining LLMs with KGs to address biomedical challenges, opening new avenues for drug design and precision medicine research.
Indexed as
Identifiers
41222841What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.